Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.37 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | NQO2 | P16083 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | RGS17 | Q9UGC6 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507560 | 1.00 | AOC3 (0.50) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL11547575 | 0.78 | TXNRD1 (0.39) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| Hydrochloric Acid SCHEMBL31668880 | 0.77 | TXNRD1 (0.38) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| Hydrochloric Acid SCHEMBL30749426 | 0.77 | TXNRD1 (0.38) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL14012978 | 0.75 | NQO2 (0.44) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL1172231 | 0.75 | TXNRD1 (0.37) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL3672985 | 0.75 | AOC3 (0.50) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL12865263 | 0.75 | AOC3 (0.50) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL14720885 | 0.75 | AOC3 (0.42) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL174080 | 0.75 | TXNRD1 (0.37) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118251393-A | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230365589-A1 | NOVEL AMINE DERIVATIVES | Sumitomo Pharma Co., Ltd. (JP) | 2023-11-16 | — | — | US | disclosed |
| US-20230365589-A1 | NOVEL AMINE DERIVATIVES | Sumitomo Pharma Co., Ltd. (JP) | 2023-11-16 | — | — | US | disclosed |
| US-20230365589-A1 | NOVEL AMINE DERIVATIVES | Sumitomo Pharma Co., Ltd. (JP) | 2023-11-16 | — | — | US | disclosed |
| EP-4215534-A1 | AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-26 | — | — | EP | disclosed |
| EP-4215534-A1 | AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-116209441-A | Novel amine derivatives | 住友制药株式会社 | 2023-06-02 | — | — | CN | disclosed |
| US-20230138851-A1 | NOVEL ALKYNE DERIVATIVES | CARNA BIOSCIENCES, INC. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230138851-A1 | NOVEL ALKYNE DERIVATIVES | CARNA BIOSCIENCES, INC. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| EP-1453492-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| EP-1409481-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| US-20040034046-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | US | disclosed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003047582-A1 | QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | AOC3 3818/4885TXNRD1 503/4885TXNRD3 1947/4885 |
| US-20230138851-A1 | NOVEL ALKYNE DERIVATIVES | DYRK1B, DYRK3, DYRK2 | AOC3 3131/4885TXNRD1 2029/4885TXNRD3 1721/4885 |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ABL1, FLT3, JAK2 | AOC3 3648/4885TXNRD1 1155/4885TXNRD3 2622/4885 |
| US-20040034046-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | AOC3 3746/4885TXNRD1 941/4885TXNRD3 1371/4885 |
| US-20230365589-A1 | NOVEL AMINE DERIVATIVES | DYRK2, DYRK1A, DYRK1B | AOC3 1312/4885TXNRD1 2372/4885TXNRD3 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.